中国真菌学杂志 2022, Vol. 17 Issue (5): 435-440.
综述 上一篇
段艳1,2, 徐媛1, 雷雯朴1,2, 杨长青2, 张晋萍1
收稿日期:2022-04-16
发布日期:2022-10-26
通讯作者:
张晋萍,E-mail:zjp16500@163.com;杨长青,E-mail:ycq0315@yahoo.com
E-mail:zjp16500@163.com;ycq0315@yahoo.com
作者简介:段艳,女(汉族),硕士研究生在读.E-mail:1908472951@qq.com
Received:2022-04-16
Published:2022-10-26
中图分类号:
段艳, 徐媛, 雷雯朴, 杨长青, 张晋萍. 非HIV人群感染耶氏肺孢子菌肺炎的诊治研究进展[J]. 中国真菌学杂志, 2022, 17(5): 435-440.
| [1] ASAI N, MOTOJIMA S, OHKUNI Y, et al. Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection[J]. J Infect Chemother, 2012, 18(6):898-905. [2] FISHMAN J A. Pneumocystis jiroveci[J]. Semin Respir Crit Care Med, 2020, 41(1):141-157. [3] ROUX A, CANET E, VALADE S, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France[J]. Emerg Infect Dis, 2014, 20(9):1490-1497. [4] TASAKA S. Recent advances in the diagnosis and management of pneumonia[J]. Tuberc Respir Dis (Seoul), 2020, 83(2):132-140. [5] SALZER H J F, SCHÄFER G, HOENIGL M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with pneumocystis jirovecii pneumonia[J]. Respiration,2018,96(1):52-65. [6] TASAKA S, KOBAYASHI S, KAMATA H, et al. Cytokine profiles of bronchoalveolar lavage fluid in patients with pneumocystis pneumonia. Microbiol Immunol 2010,54(7):425-433. [7] BIENVENU A L, TRAORE K, PLEKHANOVA I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients[J]. Int Infect Dis, 2016, 46:11-17. [8] CATHERINOT E, LANTERNIER F, BOUGNOUX ME, et al. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am, 2010,24(1):107-138. [9] OLADELE R O, OTU A A, RICHARDSON M D, et al. Diagnosis and management of Pneumocystis pneumonia in resource-poor settings[J]. J Health Care Poor Underserved, 2018, 29(1):107-158. [10] ALANIO A, HAUSER P M, LAGROU K, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients[J].J Antimicrob Chemother, 2016, 71(9):2386-2396. [11] OMBATH P T, THONGPISARASYA J, CHULANETRA M, et al. Quantitative PCR to discriminate between pneumonia and colonization in HIV and non-HIV immunocompromised patients[J]. Front Microbiol, 2021, 12:729193. DOI:10.3389/fmicb.2021.729193. [12] SASSO M, CHASTANG-DUMAS E, BASTIDE S, et al. Performances of four real-time PCR assays for diagnosis of pneumocystis jirovecii pneumonia[J]. J Clin Microbiol, 2016, 54(3):625-630. [13] GUILLAUD-SAUMUR T, NEVEZ G, BAZIRE A, et al. Comparison of a commercial real-time PCR assay, RealCycler© PJIR kit, progenie molecular, to an in-house real-time PCR assay for the diagnosis of Pneumocystis jirovecii infections[J]. Diagn Microbiol Infect Dis, 2017, 87(4):335-337. [14] ZHANG F, CHEN J, HUANG H, et al. Application of metagenomic next-generation sequencing in the diagnosis and treatment guidance of Pneumocystis jirovecii pneumonia in renal transplant recipients[J]. Eur J Clin Microbiol Infect Dis, 2021, 40(9):1933-1942. [15] JIANG J, BAI L, YANG W, et al. Metagenomic next-generation sequencing for the diagnosis of pneumocystis jirovecii pneumonia in non-HIV-infected patients:a retrospective study[J]. Infect Dis Ther, 2021, 10(3):1733-1745. [16] KARAGEORGOPOULOS D E, QU J M, KORBILA I P, et al. Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia:a meta-analysis[J].Clin Microbiol Infect, 2013, 19(1):39-49. [17] LI W-J, GUO Y-L, LIU T-J, et al. Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan:a bivariate meta-analysis and systematic review[J]. J Thorac Dis, 2015, 7(12):2214-2225. [18] DEL CORPO O, BUTLER-LAPORT G, SHEPPARD DC, et al. Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia:a systematic review and meta-analysis[J]. Clin Microbiol Infect, 2020;26(9):1137-1143. [19] JIN F, LIU X H, CHEN W C, et al. High initial (1, 3) Beta-d-Glucan concentration may be a predictor of satisfactory response of caspofungin combined with TMP/SMZ for HIV-negative patients with moderate to severe Pneumocystis jirovecii pneumonia[J]. Int J Infect Dis, 2019, 88:141-148.DOI:10.1016/j.ijid.2019.08.015. [20] TASAKA S, HASEGAWA N, KOBAYASHI S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia[J]. Chest, 2007, 131(4):1173-1180. [21] SCHMIDT J J, LUECK C, ZIESING S, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults:a retrospective analysis over 17 years[J]. Crit Care, 2018, 22(1):307. [22] CHEN Y H, FANG X Y, LI Y T, et al. Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China[J]. Braz J Microbiol, 2020, 51(3):1061-1069. [23] MERALI S, VARGAS D, FRANKLIN M, et al. S-adenosylmethionine and Pneumocystis carinii[J]. J Biol Chem, 2000, 275(20):14958-14963. [24] TASAKA S, TOKUDA H, SAKAI F, et al. Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases:a multicenter study[J]. Internal Med, 2010, 49(4):273-281. [25] Zhu M, Ye N, Xu J. Clinical characteristics and prevalence of dihydropteroate synthase gene mutations in Pneumocystis jirovecii-infected AIDS patients from low endemic areas of China[J]. PLoS One. 2020,15(9):e0238184. [26] WEYANT RB, KABBAN D, DOUCETTE K, et al. Pneumocystis jirovecii:a review with a focus on prevention and treatment[J]. Expert Opin Pharmacother. 2021,22(12):1579-1592. [27] 王玺,王广发,金哲,等.克林霉素联合伯氨喹补救治疗非HIV感染的肺孢子菌肺炎患者的效果[J].中华医学杂志,2017,97(22):1734-1736. [28] LIMPER A H, KNOX K S, SAROSI G A, et al. An official American thoracic society statement:treatment of fungal infections in adult pulmonary and critical care patients[J]. Am J Respir Crit Care Med, 2011, 183(1):96-128. [29] AGUILAR-ZAPATA D, PETRAITIENE R, PETRAITIS V. Echinocandins:The expanding antifungal armamentarium[J].Clin Infect Dis, 2015, 61(Suppl 6):S604-11. [30] 张诗琪,程德云.棘白菌素类抗真菌药物的临床应用进展[J].医学综述,2020,26(5):986-990. [31] LEE W S, HSUEH P R, HSIEH T C, et al. Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia[J]. J Microbiol Immunol Infect, 2017, 50(4):547-548. [32] LOBO M L, ESTEVES F, DE SOUSA B, et al. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia:a pilot study in mice[J]. PLoS One, 2013, 8(8):e70619. [33] QUEENER SF,CODY V,PACEJ,et al. Trimethoprim resistance of dihydrofolate reductase (DHFR) variants from clinical isolates of Pneumocystis jirovecii[J]. Antimicrob Agents Chemother,2013,57(10):4990-4998. [34] TIAN Q, SI J, JIANG F, et al. Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection[J]. HIV Med, 2021, 22(4):307-313. [35] 宋贤,普琳梅,马翠莲,等.复方磺胺甲噁唑联合卡泊芬净治疗卡氏肺孢子菌肺炎疗效和安全性的Meta分析[J].医药导报,2017,36(12):1415-1418. [36] ZHANG G, CHEN M, ZHANG S, et al. Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe Pneumocystis pneumonia[J]. Exp Ther Med, 2018, 15(2):1594-1601. [37] ASSAL M, LAMBERT J, CHOW-CHINE L, et al. Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia:A propensity score analysis[J]. PLoS One. 2021,16(4):e0250611. [38] MUNDO W, MORALES-SHNAIDER L, TEWAHADE S, et al. Lower mortality associated with adjuvant corticosteroid therapy in non-HIV-infected patients with pneumonia:a single-institution retrospective US cohort study[J]. Open Forum Infect Dis, 2020, 7(9):ofaa354. [39] DING L, HUANG H, WANG H, et al. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure:a systemic review and meta-analysis of observational studies[J]. Ann Intensive Care,2020,10(1):34. |
| [1] | 郑祎, 何云, 刘甲野, 贺守第, 孙丽琴, 王辉. 血清(1,3)-β-D葡聚糖试验与血清半乳甘露聚糖试验对马尔尼菲篮状菌病的诊断价值[J]. 中国真菌学杂志, 2022, 17(5): 385-390. |
| [2] | 石海燕, 陈美, 张丽, 孙毅, 曾同祥, 柳兵, 张秋秋. 桔青霉引起透明丝孢霉病1例及文献总结[J]. 中国真菌学杂志, 2022, 17(4): 304-307. |
| [3] | 中国体癣和股癣诊疗指南工作组. 中国体癣和股癣诊疗指南(基层实践版2022)[J]. 中国真菌学杂志, 2022, 17(3): 177-182. |
| [4] | 卢贵全, 沙嫣懿, 张军民, 张静. 两性霉素B抗真菌治疗进展[J]. 中国真菌学杂志, 2022, 17(3): 247-250. |
| [5] | 中国手癣和足癣诊疗指南工作组. 中国手癣和足癣诊疗指南(科普版2022)[J]. 中国真菌学杂志, 2022, 17(2): 89-93. |
| [6] | 马舒君, 张芙蓉, 陶苏江, 余永涛, 王英. 鼻脑型毛霉病2例及相关文献分析[J]. 中国真菌学杂志, 2022, 17(2): 109-114. |
| [7] | 陈显振, 朱信霖, 姜伟伟, 扈东营, 张克明, 方文捷, 潘炜华, 刘晓刚, 廖万清. 烟酰胺及联合伊曲康唑体外抗烟曲霉活性研究[J]. 中国真菌学杂志, 2022, 17(2): 124-128. |
| [8] | 张传明, 曹泓宇, 孙继德, 牛司强, 王詝, 蒲姝丽, 徐绣宇. 血清和支气管肺泡灌洗液GM试验对非粒细胞缺乏患者不同类型肺曲霉病的诊断价值分析[J]. 中国真菌学杂志, 2022, 17(2): 146-151. |
| [9] | 梁毅, 申颖. 肺孢子菌肺外感染的临床表现和诊治研究进展[J]. 中国真菌学杂志, 2022, 17(2): 163-167. |
| [10] | 秦玉璘, 王晓娟, 曹永兵, 吕权真, 韩冰. 外阴阴道念珠菌病的发生机制及免疫研究进展[J]. 中国真菌学杂志, 2022, 17(2): 173-176. |
| [11] | 甲真菌病指南专家工作组. 中国甲真菌病诊疗指南(2021年版)[J]. 中国真菌学杂志, 2022, 17(1): 1-7. |
| [12] | 尚元元, 李可心, 马春梅, 李莎莎, 扈容英, 杨文君. 定量PCR检测联合G试验及GM试验对侵袭性真菌感染早期诊断的价值[J]. 中国真菌学杂志, 2021, 16(6): 367-372. |
| [13] | 向仕钊, 杜宇. 宏基因组新一代测序技术快速诊断耶氏肺孢子菌肺炎1例[J]. 中国真菌学杂志, 2021, 16(6): 400-402. |
| [14] | 余茜, 闻轶旸, 高志琴, 杨连娟. DNA微阵列芯片在皮肤分枝杆菌感染中的早期诊断价值[J]. 中国真菌学杂志, 2021, 16(4): 243-246,256. |
| [15] | 张馨予, 潘开素, 罗宏, 郑冬燕, 郑艳青, 曹存巍, 梁纲. 中药小檗碱协同抗真菌药对马尔尼菲篮状菌的体外药敏试验研究[J]. 中国真菌学杂志, 2021, 16(3): 176-181. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
